Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs

Nihon University

Status: Completed

Conditions: Polypoidal Choroidal Vasculopathy

Study type: Observational

Funder types: Other

Identifiers

NCT01271426

NihonU-1

Details and patient eligibility

About

To determine whether complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes have a pharmacogenetic effect on the treatment of polypoidal choroidal vasculopathy (PCV) with ranibizumab.

Enrollment: 74 patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of Polypoidal choroidal vasculopathy
• must have injection of Ranibizumab

Exclusion criteria